Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

Healthcare distributor and services company McKesson (NYSE:MCK) will be reporting results this Wednesday after market close.

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

With a stock down nearly 50% over the last 52 weeks, investors in Guardant Health (GH -2.49%) haven't had a lot to cheer about this year. The last couple of days, however, may be changing that.

Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute ...

If Guardant Health can capture a significant share of these markets, its long-term returns could make the 360% gain since its IPO look like chump change. I think that this stock has the kind of X ...

Guardant Health thinks around 700,000 patients in the U.S. could eventually benefit from advanced-stage cancer screening, which would drive up sales to around $6 billion annually.